Proprietary AI analyst is now available

Abbott Valuation Multiples

Discover Abbott's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker and more.

Abbott Overview

About Abbott

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.


Founded

1900

HQ

United States

Employees

115.0K

Website

abbott.com

Financials (LTM)

Revenue: $47B
EBITDA: $12B

EV

$185B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Abbott Financials

Abbott reported last 12-month revenue of $47B and EBITDA of $12B.

In the same LTM period, Abbott generated $27B in gross profit, $12B in EBITDA, and $9B in net income.

Revenue (LTM)


Abbott P&L

In the most recent fiscal year, Abbott reported revenue of $44B and EBITDA of $12B.

Abbott is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 27%, and net margin of 20%.

See analyst estimates for Abbott
LTMLast FY202320242025202620272028
Revenue$47B$44B$40B$42B$44B
Gross Profit$27B$25B$22B$23B$25B
Gross Margin57%56%55%55%56%
EBITDA$12B$12B$11B$11B$12B
EBITDA Margin26%27%26%26%27%
EBIT Margin23%23%16%16%18%
Net Profit$9B$9B$6B$13B$7B
Net Margin20%20%14%32%15%
Net Debt-$4B---

Financial data powered by Morningstar, Inc.

Abbott Stock Performance

Abbott has current market cap of $158B, and enterprise value of $185B.

Market Cap Evolution


Abbott's stock price is $90.78.

Abbott share price increased by 6.1% in the last 30 days, and decreased by 33.3% in the last year.

Abbott has an EPS (earnings per share) of $5.19.

See more trading valuation data for Abbott
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$185B$158B4.4%6.1%-11.6%-33.3%$5.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Abbott Valuation Multiples

Abbott trades at 3.9x EV/Revenue multiple, and 14.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Abbott

EV / Revenue (LTM)


Abbott Financial Valuation Multiples

As of June 5, 2026, Abbott has market cap of $158B and EV of $185B.

Abbott has a P/E ratio of 17.1x.

LTMLast FY202320242025202620272028
EV/Revenue3.9x4.2x4.6x4.4x4.2x
EV/EBITDA14.9x15.3x17.5x17.1x15.3x
EV/EBIT17.0x17.9x28.5x27.1x23.0x
EV/Gross Profit6.9x7.4x8.4x8.0x7.4x
P/E17.1x17.5x27.6x11.8x24.2x
EV/FCF20.8x20.3x36.5x29.1x25.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Abbott Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Abbott Margins & Growth Rates

Abbott grew revenue by 14% and EBITDA by 10% in the last fiscal year.

In the most recent fiscal year, Abbott reported gross margin of 56%, EBITDA margin of 27%, and net margin of 20%.

See estimated margins and future growth rates for Abbott

Abbott Margins

Last FY202420252026202720282029
Gross Margin56%55%56%58%
EBITDA Margin27%26%27%26%
EBIT Margin23%16%18%23%
Net Margin20%32%15%19%
FCF Margin20%15%17%17%

Abbott Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth14%5%6%14%
Gross Profit Growth16%5%8%16%
EBITDA Growth10%2%12%10%
EBIT Growth13%5%18%45%
Net Profit Growth6%134%(51%)47%
FCF Growth(5%)26%16%17%

Data powered by FactSet, Inc. and Morningstar, Inc.

Abbott Operational KPIs

Abbott's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Abbott's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Abbott's Rule of X is 61% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Abbott
LTMLast FY202320242025202620272028
Rule of 4038%40%---
Bessemer Rule of X55%61%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue7%7%7%7%7%
Opex to Revenue-38%39%39%38%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Abbott Competitors

Abbott competitors include Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker, Medtronic, Siemens, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories and Siemens Healthineers.

Most Abbott public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Intuitive Surgical14.3x13.4x33.0x30.3x
Thermo Fisher Scientific4.9x4.8x19.0x18.9x
Danaher5.9x5.8x18.8x18.3x
Stryker5.1x4.9x17.7x17.1x
Medtronic3.7x3.4x13.5x12.3x
Siemens3.1x3.0x15.3x16.6x
Boston Scientific4.1x4.0x13.2x12.7x
Edwards Lifesciences7.8x7.4x26.1x24.4x

This data is available for Pro users. Sign up to see all Abbott competitors and their valuation data.

Start Free Trial

Acquisitions by Abbott

Abbott has acquired 13 companies to date.

Last acquisition by Abbott was on November 20th 2025. Abbott acquired Exact Sciences for $21B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Abbott

Exact Sciences
Bigfoot Biomedical
Cardiovascular Systems
Walk Vascular
Description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors.
Cardiovascular Systems, Inc. is a medical technology company commercializing atherectomy systems for peripheral and coronary artery disease. Traded on NASDAQ as CSII, its Diamondback 360 and Orion platforms address calcified lesions in PAD and CAD treatments. The Predator 360 peripheral orbital atherectomy system supports vessel preparation for stenting. Headquartered in St. Paul, Minnesota, CSI serves interventional cardiologists and vascular surgeons across the United States with over 700,000 procedures performed.
-
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Madison, WI
San Jose, CA
Saint Paul, MN
-
Deal Date20 Nov 20255 Sep 20238 Feb 20232 Sep 2021
Valuation$21Bundisclosed$851Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Abbott acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Abbott

Abbott has invested in 4 companies to date.

Latest investment by Abbott was on May 12th 2026. Abbott invested in NVision Imaging Technologies in their $38M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Abbott

NVision Imaging Technologies
WHOOP
Bigfoot Biomedical
Bigfoot Biomedical
Description
NVision Imaging Technologies is a biotech company advancing MRI diagnostics through hyperpolarized metabolite imaging. Their platform uses quantum spin alignment to visualize tumor metabolism in real-time without radiation. Based in Belmont, California, NVision's technology detects early cancer responses to chemotherapy. Clinical trials at Stanford University validate its use in prostate and breast imaging. Founded in 2015, the firm raised Series A funding to commercialize agents compatible with standard 3T MRI scanners.
WHOOP offers a wearable performance optimization system with the WHOOP Strap 3.0 that monitors physiological data continuously. It tracks strain, recovery, and sleep for athletes, coaches, and teams to optimize training, prevent injuries, and forecast performance. Boston-headquartered WHOOP serves elite sports professionals, military units, and fitness enthusiasts with actionable insights from 24/7 heart rate variability, respiratory rate, and resting heart rate metrics.
Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors.
Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors.
HQ CountryGermanyUnited StatesUnited StatesUnited States
HQ City
Ulm
Boston, MA
San Jose, CA
San Jose, CA
Deal Date12 May 202630 Mar 202613 Jan 202021 Mar 2018
RoundSeries BSeries GSeries CSeries B
Raised$38M$575M$55M$18M
InvestorsAbbott; Entrée Capital; Matterwave Ventures; Playground GlobalMacquarie Capital; Qatar Investment Authority; 2PointZero; Craig Shapiro; Mayo Clinic; Promus Ventures; Mubadala Capital Ventures; Tom Loverro; Rory McIlroy; Abbott; Accomplice; Mathieu van der PoelAbbott; Cormorant Asset Management; Janus Henderson Investors; Quadrant Capital Advisors; Senvest Capital; Smile GroupAbbott; Cormorant Asset Management; Janus Capital Group; JDRF T1D Fund; Quadrant Capital Advisors; Senvest Capital; Visionnaire Ventures; Xplorer Capital
Valuationundisclosed$10Bundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Abbott investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Abbott

When was Abbott founded?Abbott was founded in 1900.
Where is Abbott headquartered?Abbott is headquartered in United States.
How many employees does Abbott have?As of today, Abbott has over 115K employees.
Who is the CEO of Abbott?Abbott's CEO is Robert B. Ford.
Is Abbott publicly listed?Yes, Abbott is a public company listed on NYSE.
What is the stock symbol of Abbott?Abbott trades under ABT ticker.
When did Abbott go public?Abbott went public in 1949.
Who are competitors of Abbott?Abbott main competitors include Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker, Medtronic, Siemens, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers.
What is the current market cap of Abbott?Abbott's current market cap is $158B.
What is the current revenue of Abbott?Abbott's last 12 months revenue is $47B.
What is the current revenue growth of Abbott?Abbott revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of Abbott?Current revenue multiple of Abbott is 3.9x.
What is the current EBITDA of Abbott?Abbott's last 12 months EBITDA is $12B.
What is Abbott's EBITDA margin?Abbott's last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Abbott?Current EBITDA multiple of Abbott is 14.9x.
What is the current FCF of Abbott?Abbott's last 12 months FCF is $9B.
What is Abbott's FCF margin?Abbott's last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Abbott?Current FCF multiple of Abbott is 20.8x.
How many companies Abbott has acquired to date?As of June 2026, Abbott has acquired 13 companies.
What was the largest acquisition by Abbott?$25B acquisition of St. Jude Medical on 28th April 2016 was the largest M&A Abbott has done to date.
What companies Abbott acquired?Abbott acquired St. Jude Medical, Exact Sciences, Alere, CFR Pharmaceuticals, Cardiovascular Systems, Veropharm, Tendyne Holdings, Topera, Cephea Valve Technologies, Walk Vascular, and 3 other companies.
In how many companies Abbott has invested to date?As of June 2026, Abbott has invested in 4 companies.
What was the last Abbott investment?On 12th May 2026 Abbott invested in NVision Imaging Technologies, participating in a $38M Series B round, alongside Entrée Capital, Matterwave Ventures, and Playground Global.
In what companies Abbott invested in?Abbott invested in WHOOP, Bigfoot Biomedical, NVision Imaging Technologies, and SetPoint Medical.

See public comps similar to Abbott

Lists including Abbott

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial